StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Stock analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS stock opened at $0.03 on Wednesday. The stock has a market cap of $1.22 million, a PE ratio of 0.00 and a beta of 1.62. The stock has a 50-day moving average of $0.03 and a 200-day moving average of $0.04. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.